240 related articles for article (PubMed ID: 32352559)
1. Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Br J Pharmacol; 2020 Aug; 177(16):3691-3711. PubMed ID: 32352559
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655
[TBL] [Abstract][Full Text] [Related]
3. Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Nitta K; Shi S; Nagai T; Kanasaki M; Kitada M; Srivastava SP; Haneda M; Kanasaki K; Koya D
Biomed Res Int; 2016; 2016():9172157. PubMed ID: 27088094
[TBL] [Abstract][Full Text] [Related]
4. N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.
Nagai T; Kanasaki M; Srivastava SP; Nakamura Y; Ishigaki Y; Kitada M; Shi S; Kanasaki K; Koya D
Biomed Res Int; 2014; 2014():696475. PubMed ID: 24783220
[TBL] [Abstract][Full Text] [Related]
5. Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.
Srivastava SP; Shi S; Kanasaki M; Nagai T; Kitada M; He J; Nakamura Y; Ishigaki Y; Kanasaki K; Koya D
Sci Rep; 2016 Jul; 6():29884. PubMed ID: 27425816
[TBL] [Abstract][Full Text] [Related]
6. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
7. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline.
Azizi M; Junot C; Ezan E; Ménard J
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
10. Endothelial FGFR1 (Fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice.
Li J; Liu H; Srivastava SP; Hu Q; Gao R; Li S; Kitada M; Wu G; Koya D; Kanasaki K
Hypertension; 2020 Dec; 76(6):1935-1944. PubMed ID: 33131311
[TBL] [Abstract][Full Text] [Related]
11. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
12. N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.
Kanasaki K
J Diabetes Investig; 2020 May; 11(3):516-526. PubMed ID: 31997585
[TBL] [Abstract][Full Text] [Related]
13. Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats.
Zhang L; Xu LM; Chen YW; Ni QW; Zhou M; Qu CY; Zhang Y
World J Gastroenterol; 2012 Oct; 18(37):5283-8. PubMed ID: 23066324
[TBL] [Abstract][Full Text] [Related]
14. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
15. CD-1
Mizunuma Y; Kanasaki K; Nitta K; Nakamura Y; Ishigaki Y; Takagaki Y; Kitada M; Li S; Liu H; Li J; Usui I; Aso Y; Koya D
J Diabetes Investig; 2020 Nov; 11(6):1470-1481. PubMed ID: 32472621
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Plasma N-acetyl-seryl-aspartyl-lysyl-proline Level in Stable Kidney Transplant Recipients.
Suzuki Y; Katagiri F; Sato F; Fujioka K; Sato Y; Fujioka T; Sato Y; Mimata H; Itoh H
Clin Lab; 2016 Jul; 62(7):1323-1328. PubMed ID: 28164637
[TBL] [Abstract][Full Text] [Related]
17. Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.
Zhang Y; Zhang ZG; Chopp M; Meng Y; Zhang L; Mahmood A; Xiong Y
J Neurosurg; 2017 Mar; 126(3):782-795. PubMed ID: 28245754
[TBL] [Abstract][Full Text] [Related]
18. Significant decrease in plasma N-acetyl-seryl-aspartyl-lysyl-proline level in patients with end stage renal disease after kidney transplantation.
Suzuki Y; Katagiri F; Sato F; Fujioka K; Sato Y; Fujioka T; Sato Y; Mimata H; Itoh H
Biol Pharm Bull; 2014; 37(6):1075-9. PubMed ID: 24882420
[TBL] [Abstract][Full Text] [Related]
19. The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.
Eriguchi M; Bernstein EA; Veiras LC; Khan Z; Cao DY; Fuchs S; McDonough AA; Toblli JE; Gonzalez-Villalobos RA; Bernstein KE; Giani JF
J Am Soc Nephrol; 2018 Oct; 29(10):2546-2561. PubMed ID: 30185469
[TBL] [Abstract][Full Text] [Related]
20. N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.
Kanasaki K; Nagai T; Nitta K; Kitada M; Koya D
Front Pharmacol; 2014; 5():70. PubMed ID: 24782774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
